To date, the OX2R agonist TAK-861 has shown no hepatotoxicity in trials, with adverse events primarily mild to moderate (e.g., controllable insomnia, urinary urgency, and frequency), suggesting strong potential for clinical application. This evidence concerns the gene HCRTR2 and insomnia measurement.